|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1718192021222324252627...3940» |
- |||| Abilify MyCite (aripiprazole tablets embedded with sensor) / Otsuka
Enrollment open, Adherence: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder (clinicaltrials.gov) - Apr 8, 2014
P2, N=65, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Not yet recruiting --> Recruiting
- |||| aripiprazole / Generic mfg., olanzapine / Generic mfg., haloperidol / Generic mfg.
Trial completion: GiSAS: Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia (clinicaltrials.gov) - Apr 8, 2014
P4, N=300, Completed, Sponsor: Mario Negri Institute for Pharmacological Research
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change: A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial (clinicaltrials.gov) - Apr 6, 2014
P3, N=1785, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed N=1340 --> 1785
- ||| ulotaront (SEP-363856) / Otsuka, PsychoGenics
Trial completion: A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (clinicaltrials.gov) - Apr 3, 2014
P1, N=60, Completed, Sponsor: Sunovion
N=1340 --> 1785 Active, not recruiting --> Completed
- Enrollment open: Implementation of Illness Management and Recovery in Mental Health Services (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=130, Recruiting, Sponsor: University Hospital, Akershus
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| lurasidone / Generic mfg.
Enrollment change: A Twelve Week, Open Label Extension Study in Patients With Schizophrenia (clinicaltrials.gov) - Apr 1, 2014
P3, N=191, Completed, Sponsor: Sunovion
Not yet recruiting --> Recruiting N=250 --> 191
- Enrollment open: CAST: Optimizing Cognitive Remediation Outcomes in Schizophrenia (clinicaltrials.gov) - Apr 1, 2014
P=N/A, N=80, Recruiting, Sponsor: University of California, San Francisco
N=250 --> 191 Not yet recruiting --> Recruiting
- Enrollment open: Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant Obsessive-compulsive Symptoms in Patients With Schizophrenia (clinicaltrials.gov) - Apr 1, 2014
P=N/A, N=12, Recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| lurasidone / Generic mfg.
Trial completion: A Twelve Week, Open Label Extension Study in Patients With Schizophrenia (clinicaltrials.gov) - Apr 1, 2014
P3, N=191, Completed, Sponsor: Sunovion
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia (clinicaltrials.gov) - Mar 31, 2014
P2, N=36, Completed, Sponsor: Yale University
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment closed: Feedback and Psychotherapeutic Competencies (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=20, Active, not recruiting, Sponsor: Goethe University
Recruiting --> Completed Recruiting --> Active, not recruiting
- acetylcysteine solution / Generic mfg.
Enrollment closed: NACSZ: N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia (clinicaltrials.gov) - Mar 30, 2014
P1, N=24, Active, not recruiting, Sponsor: VA Greater Los Angeles Healthcare System
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed: TTIM: Improving Outcomes for Individuals With Serious Mental Illness and Diabetes (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=212, Active, not recruiting, Sponsor: Case Western Reserve University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| bitopertin (DISC-1459) / Disc Medicine
Enrollment closed: A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306) (clinicaltrials.gov) - Mar 30, 2014
P3, N=596, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| bitopertin (DISC-1459) / Disc Medicine
Enrollment closed: A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305) (clinicaltrials.gov) - Mar 30, 2014
P3, N=601, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- PF-06412562 / Pfizer, Cerevel Therap
Enrollment change: A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers (clinicaltrials.gov) - Mar 26, 2014
P1, N=40, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting N=50 --> 40
- | PF-06412562 / Pfizer, Cerevel Therap
Trial completion: A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers (clinicaltrials.gov) - Mar 26, 2014
P1, N=40, Completed, Sponsor: Pfizer
N=50 --> 40 Recruiting --> Completed
- Trial initiation date: A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia (clinicaltrials.gov) - Mar 24, 2014
P4, N=240, Not yet recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Initiation date: Aug 2013 --> Jun 2014
- Trial completion: Acute Glycine Pharmacodynamic Study (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=21, Completed, Sponsor: Mclean Hospital
Initiation date: Aug 2013 --> Jun 2014 Active, not recruiting --> Completed
- ||| ulotaront (SEP-363856) / Otsuka, PsychoGenics
Enrollment open: Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics (clinicaltrials.gov) - Mar 23, 2014
P1, N=108, Recruiting, Sponsor: Sunovion
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- quetiapine / Generic mfg.
Enrollment change: A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=60, Completed, Sponsor: Guang Dong Provincial Mental Health Institute
Not yet recruiting --> Recruiting N=80 --> 60
- quetiapine / Generic mfg.
Trial completion: A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=60, Completed, Sponsor: Guang Dong Provincial Mental Health Institute
N=80 --> 60 Recruiting --> Completed
- ||| Enrollment open: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (clinicaltrials.gov) - Mar 19, 2014
P1, N=265, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed: Nonconvulsive Electrotherapy: a Proof-of-concept Trial (clinicaltrials.gov) - Mar 19, 2014
P1, N=16, Active, not recruiting, Sponsor: University of Maryland
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| lurasidone / Generic mfg.
Enrollment change: Lurasidone Extended Use Study (clinicaltrials.gov) - Mar 18, 2014
P3, N=162, Completed, Sponsor: Sunovion
Recruiting --> Active, not recruiting N=600 --> 162
- ||||||| lurasidone / Generic mfg.
Trial completion: Lurasidone Extended Use Study (clinicaltrials.gov) - Mar 18, 2014
P3, N=162, Completed, Sponsor: Sunovion
N=600 --> 162 Recruiting --> Completed
- Enrollment change: Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia (clinicaltrials.gov) - Mar 17, 2014
P2, N=14, Completed, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Completed N=36 --> 14
- | Rykindo (risperidone extended release microspheres) / Luye Group
New P1/2 trial: Bioavailability of LY03004 and Risperdal (clinicaltrials.gov) - Mar 17, 2014
P1/2, N=70, Not yet recruiting, Sponsor: Luye Pharma Group Ltd.
- | Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia (clinicaltrials.gov) - Mar 17, 2014
P3, N=74, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=36 --> 14 Active, not recruiting --> Completed
- Trial completion: Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia (clinicaltrials.gov) - Mar 17, 2014
P2, N=14, Completed, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- Clinical: Health Promotion and Fitness for Younger and Older Adults With SMI (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=210, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
- Enrollment closed: Acceptance and Efficacy of Live Supervision (clinicaltrials.gov) - Mar 16, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Goethe University
Recruiting --> Completed Recruiting --> Active, not recruiting
- | bitopertin (DISC-1459) / Disc Medicine
Biomarker, Trial completion: A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder (clinicaltrials.gov) - Mar 16, 2014
P1, N=31, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| bitopertin (DISC-1459) / Disc Medicine
Enrollment closed: A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (clinicaltrials.gov) - Mar 13, 2014
P3, N=626, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| New P1 trial: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (clinicaltrials.gov) - Mar 12, 2014
P1, N=265, Recruiting, Sponsor: Janssen Research & Development, LLC
- Mifeprex (mifepristone) / Danco Laboratories
Enrollment change: Treatment of Schizoaffective Disorder Using Mifepristone (clinicaltrials.gov) - Mar 11, 2014
P2/3, N=14, Terminated, Sponsor: Stanford University
Recruiting --> Active, not recruiting N=30 --> 14
- Enrollment change: Clinical and Biological Characteristics of Psychotic Depression (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=73, Completed, Sponsor: Stanford University
N=30 --> 14 N=100 --> 73
- Clinical: RCTEDSS: Randomized Controlled Trial (RCT) of a Motivational Decision Support System (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=174, Not yet recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- | Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories
New P2 trial: PRISMA-2: Pharmacokinetics and Tolerability Study of Risperidone ISM (clinicaltrials.gov) - Mar 11, 2014
P2, N=48, Recruiting, Sponsor: Rovi Pharmaceuticals Laboratories
- Trial completion: Clinical and Biological Characteristics of Psychotic Depression (clinicaltrials.gov) - Mar 11, 2014
P=N/A, N=73, Completed, Sponsor: Stanford University
N=100 --> 73 Recruiting --> Completed
- methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg.
Trial initiation date, Combination therapy: A Study of Combination Therapy in Children With ADHD (clinicaltrials.gov) - Mar 10, 2014
P4, N=99, Recruiting, Sponsor: Douglas Sears
Recruiting --> Completed Initiation date: Sep 2013 --> Mar 2014
- valacyclovir / Generic mfg.
Enrollment open: A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia (clinicaltrials.gov) - Mar 10, 2014
P2, N=175, Recruiting, Sponsor: Indiana University
Initiation date: Sep 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg.
Enrollment open, Combination therapy: A Study of Combination Therapy in Children With ADHD (clinicaltrials.gov) - Mar 10, 2014
P4, N=99, Recruiting, Sponsor: Douglas Sears
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=70, Completed, Sponsor: National Institute on Drug Abuse (NIDA)
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Abilify MyCite (aripiprazole tablets embedded with sensor) / Otsuka
Trial initiation date, Adherence: Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder (clinicaltrials.gov) - Mar 6, 2014
P2, N=65, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Completed Initiation date: Dec 2013 --> Mar 2014
- Trial completion: CRIS: Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia (clinicaltrials.gov) - Mar 6, 2014
P1/2, N=80, Completed, Sponsor: University of California, San Francisco
Initiation date: Dec 2013 --> Mar 2014 Active, not recruiting --> Completed
- | Daliresp (roflumilast) / AstraZeneca, Takeda, AbbVie
New P1 trial: Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia (clinicaltrials.gov) - Mar 4, 2014
P1, N=22, Recruiting, Sponsor: Takeda
- Clinical: Effects of a Walking Program in People With Mental Disorders (clinicaltrials.gov) - Mar 3, 2014
P=N/A, N=100, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- Enrollment open: Oxytocin as Adjunctive Therapy for Schizophrenia (clinicaltrials.gov) - Mar 2, 2014
P2, N=80, Recruiting, Sponsor: IRCCS Centro San Giovanni di Dio Fatebenefratelli
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Enrollment closed: A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia (clinicaltrials.gov) - Mar 2, 2014
P3, N=900, Active, not recruiting, Sponsor: Forest Laboratories
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting